Contacter le RP

Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.


Babbler permet aux journalistes et communicants de collaborer plus simplement.

En vous connectant, vous pourrez accéder gratuitement aux espaces presse des centaines d'entreprises de vos secteurs qui sont sur Babbler, entrer en contact direct avec leurs équipes RP mais aussi y partager vos prochains sujets !

Leurs espaces presse sont sur Babbler :

Vous êtes à 1 clic de l'inscription !


Content de vous revoir !

Communiqué de presse

Take Control / IDMPS Sanofi Diabetes Update
timer minutes de lecture minute de lecture

Copier le lien

Cliquez sur l'image pour obtenir le format original

Media Information:

Understanding why people disrupt their insulin

therapy October 5, 2018 Berlin, Germany 

Background: Diabetes management and adherence to insulin therapy 

The number of people suffering from diabetes globally is on the rise. In 2017 alone, approximately 425 million people were estimated to be living with the condition and this number is expected to escalate.1 By 2045, 629 million people are expected to be diagnosed with diabetes, particularly in countries shifting from low to middle incomes.1 In spite of many strides being made in the treatment and management of this debilitating condition, adherence to insulin therapy is often sub-optimal and it increases the risk of compromised clinical outcomes.2 Appropriate adherence can reduce complications2 and have long-term benefits for the patient. Therefore, identifying and removing barriers to therapy and understanding the reasons behind treatment disruption are key in advancing the standard of care.

Sanofi is committed to widening the understanding of real life challenges in diabetes management worldwide through the International Diabetes Management Practices Study (IDMPS). In 2016-17, the seventh wave of international observational studies investigated why people with diabetes in the developing world disrupt their insulin therapy. Sanofi is presenting the following new analysis at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany.3

Observational study identifies why people with type 1 and type 2 diabetes in the developing world discontinue their insulin treatment.

Fear of low blood sugar (hypoglycemia) events, lack of support, cost of medicines and impact on social life were the major barriers given for discontinuing insulin treatment.3

“The IDMPS data gives unique insight into how diabetes management can be improved. Identifying reasons behind why people with type 1 and type 2 diabetes discontinue insulin treatment has highlighted a real cause for concern. There is need for a multi- pronged strategy to improve treatment adherence and optimize outcomes,” said Pablo Aschner, Associate Professor of Endocrinology, Javeriana University School of Medicine, Bogotá, Colombia.

Empowering Patients to Take Control of Insulin Titration

New data, also presented at EASD this year,4 highlights the relevance of the TAKE CONTROL patient reported outcomes study. TAKE CONTROL study demonstrates the value of the Toujeo® (insulin glargine 300 Units/mL) dose adjustment algorithm, showing more effective blood sugar control when patients self-titrate Toujeo versus physician-supported titration.

The study shows that more patients using self-titration than those using physician-led titration achieved either an average blood sugar (HbA1c) below the recommended target of 7%. Similarly, more self-titrating patients achieved their overnight (fasting) blood sugar target without confirmed (<3.0 mmol/L) or severe low blood sugar requiring medical assistance (67% vs 58%), compared with those using physician-supported titration. Decrease in emotional burden through the study period was also similar in both groups, with fewer participants reporting high emotional burden in the self- vs physician-managed group (8.5% vs 12.2%) after 24 weeks.

“People living with diabetes experience reduced low blood sugar events as a major barrier to treatment adherence. The Take Control study shows that modern basal insulins are ideally suited to allow effective patient led titration to achieve good diabetes control,” said Professor David Russell-Jones, Consultant Physician at the Royal Surrey County Hospital and Professor of Diabetes and Endocrinology at the University of Surrey, UK.

In the Take Control study,4 631 adults using Toujeo to treat inadequately controlled type 2 diabetes compared the efficacy and safety of the Toujeo algorithm for dose adjustment (titration) when managed by physicians vs by the patients themselves over 24 weeks. 

Autres actualités de la marque

inscrit avec succès

Félicitations, vous êtes inscrit sur BABBLER !

Pour découvrir dès maintenant toutes les actualités qui vous attendent sur Babbler, consultez votre newsfeed !

Vos domaines ont été préselectionnés. Vous pouvez les compléter en cliquant ici